Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13543996 | 0.81 | LOXL2 (0.47) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| SCHEMBL11304060 | 0.80 | LOXL2 (0.50) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| SCHEMBL16205279 | 0.79 | TSHR (0.40) | CYP3A4SIGMAR1SLC6A4TAAR1SLC18A2 | |
| SCHEMBL15160673 | 0.79 | TSHR (0.40) | CYP3A4SIGMAR1SLC6A4TAAR1SLC18A2 | |
| SCHEMBL15161169 | 0.78 | TP53 (0.42) | TAAR1 | |
| SCHEMBL2504209 | 0.76 | KDM4E (0.68) | LOXL2KDM4ECYP3A4MAPTNCF1 | |
| SCHEMBL28734578 | 0.76 | SLC6A4 (0.39) | SLC6A4TAAR1 | |
| SCHEMBL5838111 | 0.76 | IDO1 (0.42) | TAAR1 | |
| SCHEMBL6547498 | 0.75 | SIGMAR1 (0.50) | SIGMAR1SLC6A4TAAR1SLC18A2 | |
| SCHEMBL25146600 | 0.75 | LOXL2 (0.45) | LOXL2KDM4ECYP3A4MAPTNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LOXL2 3968/4885KDM4E 1618/4885CYP3A4 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.